These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. [Treatment of sclerotic macular dystrophy]. Smidovich LE Oftalmol Zh; 1978; (6):471. PubMed ID: 714359 [No Abstract] [Full Text] [Related]
30. The use of intraocular corticosteroids. Kiernan DF; Mieler WF Expert Opin Pharmacother; 2009 Oct; 10(15):2511-25. PubMed ID: 19761356 [TBL] [Abstract][Full Text] [Related]
31. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Shah AR; Del Priore LV Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101 [TBL] [Abstract][Full Text] [Related]
32. Monitoring ocular drug therapy by analysis of aqueous samples. Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195 [TBL] [Abstract][Full Text] [Related]
33. Researchers study new treatment for macular degeneration. Mayo Clin Health Lett; 2012 May; 30(5):4. PubMed ID: 22754958 [No Abstract] [Full Text] [Related]
34. [Electroretinography in the diagnosis and monitoring of treatment for neovascular age-related macular degeneration: Communication 1]. Zueva MV; Tsapenko IV; Riabina MV; Grinchenko MI; Neroeva NV Vestn Oftalmol; 2009; 125(4):51-4. PubMed ID: 19824451 [TBL] [Abstract][Full Text] [Related]
35. Sight drug deal ends High Court challenge. Dyer C BMJ; 2008 Jul; 337():a1039. PubMed ID: 18658188 [No Abstract] [Full Text] [Related]
37. The future of cosmeceuticals: an interview with Albert Kligman, MD, PhD. Interview by Zoe Diana Draelos. Kligman A Dermatol Surg; 2005 Jul; 31(7 Pt 2):890-1. PubMed ID: 16029684 [No Abstract] [Full Text] [Related]
38. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. Jahn EM; Schneider CK N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045 [TBL] [Abstract][Full Text] [Related]
39. Impact of multiaccess infusion devices on in vitro drug delivery during multi-infusion therapy. Décaudin B; Dewulf S; Lannoy D; Simon N; Secq A; Barthélémy C; Debaene B; Odou P Anesth Analg; 2009 Oct; 109(4):1147-55. PubMed ID: 19762742 [TBL] [Abstract][Full Text] [Related]
40. Verteporfin: restriction of indications: labelling change. A welcome move. A negative risk-benefit balance in neovascular forms of ARMD with "occult" lesions. Prescrire Int; 2008 Oct; 17(97):192. PubMed ID: 19536923 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]